Eclipsebio

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrows RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of...

Rna,next generation sequencing,ngs,rna sequencing,rna-seq,epitranscriptomics,rna sequencing services,eclip,ribosome profiling,ribo-seq,genomics,translatomics,shape-map,rna structure,rna therapeutics,rna binding protein (rbp),microrna (mirna),rna modifications (m6a),iclip,merip,targetscan,and rna therapeutics

Eclipsebio operates in the Biotechnology research industry.

Eclipsebio's revenue is 11m - 100m

Eclipsebio has 11 - 50 employees.